| Business Summary | | GenStar
Therapeutics
Corporation
is
a
biotechnology
company
dedicated
to
the
development
of
gene
therapy
products
capable
of
treating
a
wide
range
of
serious
diseases.
These
range
from
liver-based
diseases
such
as
hemophilia,
to
various
types
of
cancer
and
infectious
diseases
that
include
HIV
and
AIDS.
The
Company
is
currently
focusing
on
developing
proprietary
adenoviral
and
lentiviral
vector
technologies
that
will
become
products
for
the
treatment
of
hemophilia,
prostate
cancer
and
HIV/AIDS.
GenStar's
novel
core
technology
is
the
Maximum-AD
system,
which
is
based
on
common
cold
adenoviral
vector
systems
that
facilitate
maximum
therapeutic
DNA
delivery.
Maximum-AD
has
been
bioengineered
from
the
common
cold
adenovirus,
with
all
viral
genes
removed
to
provide
safety
and
maximum
capacity
for
gene
delivery. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | GeneStar
Therapeutics
Corp.
is
a
biotechnology
company
dedicated
to
the
development
of
innovative
gene
therapy
products
for
the
treatment
of
hemophilia,
cancer
and
HIV/AIDS.
For
the
six
months
ended
6/30/01,
revenues
fell
1%
to
$72
thousand.
Net
loss
rose
22%
to
$5.6
million.
Results
reflect
decreased
research
agreement
and
grant
revenues.
Higher
loss
reflects
the
expenses
for
the
Company's
efforts
to
develop
core
technologies
and
products. | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| Paul Quadros, 53 Chairman | $134K | Robert Sobol, M.D., 47 CEO,
Director | 231K | Lee McCracken Pres
and CBO | -- | Wei-Wei Zhang, Ph.D., 42 Sr.
VP, CSO | 272K | Connie Kohne VP, Regulatory Affairs and Corp. Quality | -- | Dollar
amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|